Our latest research has demonstrated that Nuvec® loaded with pDNA encoding the ovalbumin (OVA) antigen triggered an immune response that was sufficient to have produced strong levels of antibodies specific for OVA. A strong level of antibody production is essential for a vaccine to deliver immunity. The levels of antibodies produced were greater than those of in vivo-jetPEI®, an industry standard used to deliver pDNA-OVA in pre-clinical studies. Furthermore, assessing the detailed classes of antibodies produced has shown that Nuvec® delivers a strong robust level of the specific antibodies needed for effective oncology and virology vaccines.

Fill out the form below to download the poster and see the full results.

N4 Pharma needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.